Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice

Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

(2016) Tomás José González-López et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial

(2015) Y. Wei et al.   BLOOD

Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study

(2015) Adrian Newland et al.   BRITISH JOURNAL OF HAEMATOLOGY

Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients

(2015) Jérôme Stirnemann et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial

(2015) Waleed Ghanima et al.   LANCET

Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults

(2014) D. Gomez-Almaguer et al.   BLOOD

Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration

(2014) J. B. Bussel et al.   HAEMATOLOGICA

Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients

(2014) Anil Kumar Tripathi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

(2013) S. Gudbrandsdottir et al.   BLOOD

High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia

(2013) David Gómez-Almaguer et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Romiplostim as early treatment for refractory primary immune thrombocytopenia

(2013) Anne Contis et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia

(2012) Francesco Zaja et al.   AMERICAN JOURNAL OF HEMATOLOGY

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

(2012) V. L. Patel et al.   BLOOD

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study

(2012) M. N. Saleh et al.   BLOOD

Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy

(2012) Kenjiro Mitsuhashi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immune thrombocytopenia and anticoagulation: the role of romiplostim in the early treatment

(2012) Nathan Cantoni et al.   BRITISH JOURNAL OF HAEMATOLOGY

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program

(2011) M. Khellaf et al.   BLOOD

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

(2011) C. Neunert et al.   BLOOD

Romiplostim for the early management of severe immune thrombocytopenia unresponsive to conventional treatment

(2011) Giuseppe Tagariello et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

(2010) F. Zaja et al.   BLOOD

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

(2010) David J. Kuter et al.   NEW ENGLAND JOURNAL OF MEDICINE

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD